Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

PalmERASERs The role of Palmitoylation ERASERs in cancer metastasis

Coordinator
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Spain
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101116912

What the project is doing

In the project's own words, from its summary on CORDIS.

Metastasis is the major cause of death in patients with cancer. A better understanding of the mechanisms driving metastasis is critical to develop more effective anti-cancer treatments. The fatty acid palmitate has been recently identified as fuel for metastasis-promoting pathways. However, why palmitate has such a unique pro-metastatic effect compared to other fatty acids with similar metabolic fates remains elusive.

Strikingly, I discovered that palmitoylation, a reversible post-translational protein modification driven solely by palmitate, is essential for metastasizing breast-cancer cells. Unexpectedly, I found that palmitoylation ‘erasers’, enzymes that remove the modification, are essential to sustain pro-metastatic effects of palmitate during metastatic colonization. Therefore, I hypothesize that, in palmitate-rich conditions (e.g under high-fat diet), palmitoylation anchor oncogenic proteins to membranes to get activated (functioning as a priming event), while erasers act as a rate-limiting release step, allowing primed proteins to engage in pro-metastatic signaling.

I will investigate how the dynamics of palmitoylation promote metastasis by focusing on the erasers, whose role in metastasis remains largely unexplored. Specifically, I will: 1) define how erasers influence pro-metastatic signaling events in metastasizing cells; 2) investigate how erasers activity is regulated in metastasizing cells; and 3) assess how organ microenvironments and palmitate-rich diet condition eraser activity.

I will address this by integrating multi-omics, molecular biology and mass spectrometry techniques with clinically relevant in vivo metastasis models. PalmERASERs will serve as a proof of concept for palmitoylation-based therapies with the goal of preventing or treating metastases. By focusing on the influence of diet, I will also enhance clinical translation of these findings by defining which patients will respond most effectively to palmitoylation-based therapies.

Topics

Who is involved

OrganisationCityCountryRole
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI